October 01, 2020

Roivant today announced that due to the prevalence of COVID-19 in regions with study sites and the heightened vulnerability of patients with idiopathic pulmonary fibrosis (IPF) to respiratory distress, Respivant was forced to halt its trial of RVT-1601 for the treatment of persistent cough in IPF. The results from this early-terminated study did not support continued development of RVT-1601. Multiple members of the Respivant team are being redeployed to Roivant and other Vants. Roivant is proud of the work of the Respivant team in the face of unique challenges raised by COVID-19.